Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

Slides:



Advertisements
Similar presentations
The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.
Advertisements

Diabetic Nephropathy.  Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes.  In 2001, 41,312 people with diabetes began.
Kidney Diseases Prevention. Overview The mortality rate of Nephritis, Nephrotic Syndrome, and Nephrosis (18.15 per 100,000 population) marching the 7th.
Diabetic Microvascular Disease: The Role of Glycemic Control and the Impact on Public Health Robert E. Ratner, MD MedStar Research Institute Georgetown.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
The ADVANCE trial: update and new results Jean-François Gautier Saint Louis Hospital, Paris 12 th Meeting of the Mediterranean Group for the Study of Diabetes.
ERECTILE DYSFUNCTION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Chronic Kidney Disease (CKD) Healthy Kansans 2010.
UK Renal Registry 17th Annual Report Figure 4.1. RRT treatment used by prevalent paediatric patients
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Chronic Kidney Disease (CKD) Dr. Sham Sunder. Now we know why the titanic sank !! < 0.5 % 5- 10%
Primary Cause of Kidney Failure in new ESRD patients at initiation, by ethnicity figure 2.1, combined.
Section 1: CKD Epidemiology
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Section 4: Managing progression of CKD
The LIVES Sub-analysis
2016 Annual Data Report, Vol 2, ESRD, Ch 6
Healthy People 2010 targets & levels achieved in 2000 figure hp.1
Pathophysiology and Prevention of Heart Disease in Diabetes Mellitus
First-year death rates by modality figure 8
Odd ratio of developing kidney failure figure 1
Chronic Kidney Disease in Diabetes
Mortality rates in incident ESRD patients figure 9
The IDEAL Study Reference
Hospital admissions per patient, by modality figure 5
Diabetes and Risk of CV Outcomes
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
Macrovascular Complications Microvascular Complications
Heart Rate, HF Admissions, and Readmissions
New Patient-Friendly Options for Managing Insulin Dosing
A CASE CHALLENGE IN HFrEF:
SAVE: Risk of total mortality associated with reduced kidney function
366 میلیون نفر در جهان مبتلا به دیابت هستند.
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Blood pressure control: dependence on adherence
Diabetes Increases Risk of CVD
Volume 83, Issue 3, Pages (March 2013)
Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.
Improving Management of Type 2 Diabetes in Hispanic/Latino Patients
The future of urate-lowering strategies for gout
Seizures in the Elderly: Treatment and Special Considerations
What's New From ERA-EDTA 2018?
Statins and HIV:.
The risk of DR progression as related to mean HbA1c during DCCT
SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Case 1 Presentation Case 1 (cont) Assessment and Recommendations.
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Hepatitis C: After the Diagnosis
Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study  Vasilios Papademetriou, MD, DSc, Eric.
Managing Rare CKDs.
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Pharmacotherapy for Diabetic Coronary Disease:
Meeting the challenges of the new K/DOQI guidelines
Glycemic Management in ESRD and Earlier Stages of CKD
Antithrombotic Therapy in PAD
Insulin in Diabetes Management: Effective Patient Selection Is Key
Steven J. Chadban, Natalie D. Staplin  Kidney International 
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
American Journal of Kidney Diseases
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
Achieving Lipid Targets With PCSK9 Inhibition
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Emerging Advances in Reducing Renal Complications of T2D
Lipids, the Heart, and the Kidney
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Presentation transcript:

Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes

Program Goals

Incident Counts and Adjusted Rates of ESRD by Primary Diagnosis

Adjusted 5-Year Survival by Modality and Primary Diagnosis: 1997-2001

Natural History of Diabetic Nephropathy

Percentage Chance of CV Event in 5 Years: No Diabetes

Patients Diagnosed as Having CKD Have a Greater Likelihood of Death than ESRD

Screening for Nephropathy

CKD Progresses in Stages Defined by Kidney Function: GFR

CKD Resets the Focus on CV Risk Reduction Strategies

Good Glycemic Control (Lower HbA1c) Reduces Complications

DCCT: Relationship of HbA1c to Risk of Microvascular Complications

Challenges to Screening for CKD

Other Screening and Diagnosis Considerations

Referral Considerations

Referral Considerations (cont)

Summary Points

Abbreviations

References

References (cont)

References (cont)